2025-10-23

VOLUNTARY ANNOUNCEMENT - FIRST PATENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM01

2025-10-16

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

2025-10-16

Next Day Disclosure Return

2025-10-16

COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE

2025-10-09

PLACING OF NEW H SHARES UNDER GENERAL MANDATE

2025-10-09

PLACING OF NEW H SHARES UNDER GENERAL MANDATE

2025-10-08

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 30 September 2025

2025-10-02

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE III CLINICAL TRIAL OF IMM2510

2025-10-02

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE III CLINICAL TRIAL OF IMM2510

2025-09-29

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF FOLLICULAR LYMPHOMA

2025-09-29

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF FOLLICULAR LYMPHOMA

2025-09-23

2025 Interim Report

2025-09-23

2025 Interim Report

2025-09-04

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2025

2025-09-04

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 August 2025

2025-08-26

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025

2025-08-18

VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE I CLINICAL TRIAL OF IMC-003/IMM72

2025-08-12

DATE OF BOARD MEETING

2025-08-05

Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 July 2025

2025-07-30

VOLUNTARY ANNOUNCEMENT - MILESTONE PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH AXION BIO